Thermo Fisher Scientific’s (NYSE:TMO) second-quarter results delivered something investors in the life-sciences tools sector have been waiting for: stronger evidence that the post-pandemic downturn is giving way to a broader recovery. Thermo Fisher proving that stronger organic growth and margin expansion can be sustained. Revenue and earnings beat Wall Street forecasts, organic growth accelerated to … Continue reading Thermo Fisher Q2 2026: stronger growth and guidance upgrade strengthen the recovery story